Treatment of patients with Eisenmenger's syndrome with Bosentan

被引:9
作者
Brun, Henrik
Thaulow, Erik
Fredriksen, Per Morten
Holmstrom, Henrik
机构
[1] Natl Hosp Norway, Paediat Cardiol Unit, N-0027 Oslo, Norway
[2] Natl Hosp Norway, Physiotherapy Dept, N-0027 Oslo, Norway
关键词
pulmonary hypertension; congenital heart disease; exercise testing;
D O I
10.1017/S1047951107000522
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We treated prospectively 14 patients with Eisenmenger's syndrome, with a mean age of 10 years, ranging from 3 to 18 years. Treatment continued for 12 months, and demonstrated a lasting symptomatic improvement, but no improvement in terms of mean saturation of oxygen over 24 hours. Exercise capacity, as judged by peak uptake of oxygen, worsened in the six patients able to perform a treadmill test. The symptomatic benefit from dual blockage of endothelin receptors in these patients may be due to mechanisms other than selective pulmonary vasodilatation alone.
引用
收藏
页码:288 / 294
页数:7
相关论文
共 22 条
[1]   Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease [J].
Apostolopoulou, SC ;
Manginas, A ;
Cokkinos, DV ;
Rammos, S .
HEART, 2005, 91 (11) :1447-1452
[2]   Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension [J].
Barst, RJ ;
Ivy, D ;
Dingemanse, J ;
Widlitz, A ;
Schmitt, K ;
Doran, A ;
Bingaman, D ;
Nguyen, N ;
Gaitonde, M ;
van Giersbergen, PLM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :372-382
[3]  
BOWYER JJ, 1986, BRIT HEART J, V55, P385
[4]   Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].
Channick, RN ;
Simonneau, G ;
Sitbon, O ;
Robbins, IM ;
Frost, A ;
Tapson, VF ;
Badesch, DB ;
Roux, S ;
Rainisio, M ;
Bodin, F ;
Rubin, LJ .
LANCET, 2001, 358 (9288) :1119-1123
[5]   Initial experience with Bosentan therapy in patients with the Eisenmenger syndrome [J].
Christensen, DD ;
McConnell, ME ;
Book, WM ;
Mahle, WT .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 94 (02) :261-263
[6]   Eisenmenger syndrome - Factors relating to deterioration and death [J].
Daliento, L ;
Somerville, J ;
Presbitero, P ;
Menti, L ;
Brach-Prevert, S ;
Rizzoli, G ;
Stone, S .
EUROPEAN HEART JOURNAL, 1998, 19 (12) :1845-1855
[7]  
Fredriksen PM, 1998, SCAND J MED SCI SPOR, V8, P203
[8]   Bosentan therapy in patients with Eisenmenger syndrome - A multicenter, double-blind, randomized, placebo-controlled study [J].
Galie, Nazzareno ;
Beghetti, Maurice ;
Gatzoulis, Michael A. ;
Granton, John ;
Berger, Rolf M. F. ;
Lauer, Andrea ;
Chiossi, Eleonora ;
Landzberg, Michael .
CIRCULATION, 2006, 114 (01) :48-54
[9]   Exercise testing in children with primary pulmonary hypertension [J].
Garofano, RP ;
Barst, RJ .
PEDIATRIC CARDIOLOGY, 1999, 20 (01) :61-64
[10]   Safety and tolerability of bosentan in adults with Eisenmenger physiology [J].
Gatzoulis, MA ;
Rogers, P ;
Li, W ;
Harries, C ;
Cramer, D ;
Ward, S ;
Mikhail, GW ;
Simon, J ;
Gibbs, R .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 98 (01) :147-151